Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 30, 2000

Study Completion Date

July 31, 2010

Conditions
Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

alemtuzumab

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

filgrastim

BIOLOGICAL

rituximab

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

busulfan

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

methotrexate

DRUG

mycophenolate mofetil

PROCEDURE

peripheral blood stem cell transplantation

RADIATION

radiation therapy

Trial Locations (13)

12200

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin

24116

University Hospital Schleswig-Holstein - Kiel Campus, Kiel

30625

Medizinische Hochschule Hannover, Hanover

37075

Universitaetsklinikum Goettingen, Göttingen

45122

Universitaetsklinikum Essen, Essen

66421

Universitaetsklinikum des Saarlandes, Homburg

89081

Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm, Ulm

93053

Klinikum der Universitaet Regensburg, Regensburg

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

D-20099

Asklepios Klinik St. Georg, Hamburg

D-69120

Universitaets-Kinderklinik Heidelberg, Heidelberg

D-55743

Clinic for Bone Marrow Transplantation and Hematology and Oncology, Idar-Oberstein

04103

University Hospital of Leipzig, Leipzig

All Listed Sponsors
lead

German CLL Study Group

OTHER

NCT00281983 - Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | Biotech Hunter | Biotech Hunter